Access Pharma to Conduct Cobalamin siRNA Program at CNSI Symposium

ACCESS PHARMACEUTICALS, INC. (OTC:ACCP) (BULLETIN BOARD: ACCP) , a biopharmaceutical company specializing in products for cancer and supportive care, announced that its Senior VP of R&D, David Nowotnik, Ph.D., will give two presentations today on the Company's Cobalamin siRNA program at the Novel Nanodelivery of siRNA and miRNA Symposium, hosted by the California NanoSystems Institute (CNSI) of UCLA.

Access Pharma's invited oral presentation and its poster presentation will highlight the cell targeting aspects of the Company's proprietary Cobalamin technology and the progress made by its scientist team in applying that technology to the intracellular delivery of RNAi therapeutics.

"We are delighted to have been given the opportunity to present recent data at this important meeting of leaders in the RNAi field," commented David Nowotnik, Ph.D., Access Pharma's Senior Vice President R&D. Dr. Nowotnik continued, "While RNAi therapeutics show immense promise for future treatment of a variety of diseases, their effective delivery into cells and to the nucleus of those cells remains a challenge. By using the body's natural mechanism for cellular absorption of vitamin B12, we believe that Access Pharma's Cobalamin-targeted delivery technology can play an important role in the delivery of RNAi therapeutics."

Source: http://www.accesspharma.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Abeona Therapeutics Inc.. (2019, March 19). Access Pharma to Conduct Cobalamin siRNA Program at CNSI Symposium. AZoNano. Retrieved on June 20, 2024 from https://www.azonano.com/news.aspx?newsID=18028.

  • MLA

    Abeona Therapeutics Inc.. "Access Pharma to Conduct Cobalamin siRNA Program at CNSI Symposium". AZoNano. 20 June 2024. <https://www.azonano.com/news.aspx?newsID=18028>.

  • Chicago

    Abeona Therapeutics Inc.. "Access Pharma to Conduct Cobalamin siRNA Program at CNSI Symposium". AZoNano. https://www.azonano.com/news.aspx?newsID=18028. (accessed June 20, 2024).

  • Harvard

    Abeona Therapeutics Inc.. 2019. Access Pharma to Conduct Cobalamin siRNA Program at CNSI Symposium. AZoNano, viewed 20 June 2024, https://www.azonano.com/news.aspx?newsID=18028.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.